Leading biotech company Bharat Biotech is focusing on the development and testing of a vaccine against COVID-19 virus.
The new vaccine, named ‘CoroFlu’, is being developed in association with US-based company FluGen and the University of Wisconsin-Madison.
According to reports, the vaccine, that is in the animal testing stage in the united states, is anticipated to be ready for human trials.
The CoroFlu vaccine will be manufactured on the grounds of the influenza vaccine offender of FluGen.
According to an invention by the University of Wisconsin–FluGen co-founders Yoshihiro Kawaoka and Madison virologists and Gabriele Neumann, M2SR is.
Receptor sequences will be inserted by kawaoka’s laboratory from SARS-CoV-2, which induces COVID-19 the new vaccine may cause resistance.
“Bharat Biotech in Hyderabad will subsequently start production scale-up for efficacy and safety testing in people. CoroFlu could maintain human clinical trials by October,” said the company in a statement.
Institutions and many associations are currently employed for development of a vaccine from COVID-19 that has claimed numerous lives .